ADC Linker and Conjugation Summit

Conference themes
As the proportion of clinically site-specific ADCs increases, the abundance of novel conjugation technologies diversifies, and the linker chemistry toolkit is expanded, investments in linker and conjugation technologies have become the single-biggest area of investment for ADC drug developers.

Professional congress organizer (PCO)
Hanson Wade Group

Notes
URL:
Brochure: https://go.evvnt.com/1646328-3?pid=4832

Speakers: Abbas El Sahili | CEO | Singzyme, BinQing Wei | Senior Scientist | Genentech Inc, Donglu Zhang | Senior Fellow - Drug Metabolism and Pharmacokinetics | Genentech Inc, and more.

http://go.evvnt.com/1646328-2?pid=4832

Ms. Jessica Durston